Alteration of epoxyeicosatrienoic acids in the liver and kidney of cytochrome P450 4F2 transgenic mice

Zhang,Bijun; Lai,Guangrui; Liu,Xiaoliang; Zhao,Yanyan

doi:10.3892/mmr.2016.5962

Alteration of epoxyeicosatrienoic acids in the liver and kidney of cytochrome P450 4F2 transgenic mice

Authors:
- Bijun Zhang
- Guangrui Lai
- Xiaoliang Liu
- Yanyan Zhao
View Affiliations

Affiliations: Department of Clinical Genetics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: November 23, 2016 https://doi.org/10.3892/mmr.2016.5962
Pages: 5739-5745

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Arachidonic acid (AA) can be metabolized into 20-hydroxyeicosatetraenoic acid (20-HETE) by ω-hydroxylases, and epoxyeicosatrienoic acids (EETs) by epoxygenases. The effects of EETs in cardiovascular physiology are vasodilatory, anti-inflammatory and anti‑apoptotic, which are opposite to the function to 20‑HETE. However, EETs are not stable in vivo, and are rapidly degraded to the biologically less active metabolites, dihydroxyeicosatrienoic acids, via soluble epoxide hydrolase (sEH). Western blotting, reverse transcription‑quantitative polymerase chain reaction and liquid chromatography tandem mass spectrometry were performed in order to determine target RNA and protein expression levels. In the present study, it was demonstrated that the disturbed renal 20‑HETE/EET ratio in the hypertensive cytochrome P450 4F2 transgenic mice was caused by the activation of sEH and the repression of epoxygenase activity. In addition, 20‑HETE showed an opposite regulatory effect on the endogenous epoxygenases in the liver and kidney. Given that 20‑HETE and EETs have opposite effects in multiple disease, the regulation of their formation and degradation may yield therapeutic benefits.

View Figures

View References

1	Brash AR: Arachidonic acid as a bioactive molecule. J Clin Invest. 107:1339–1345. 2001. View Article : Google Scholar : PubMed/NCBI
2	Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 82:131–185. 2002. View Article : Google Scholar : PubMed/NCBI
3	Shen HC: Soluble epoxide hydrolase inhibitors: A patent review. Expert Opin Ther Pat. 20:941–956. 2010. View Article : Google Scholar : PubMed/NCBI
4	Miyata N and Roman RJ: Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res. 41:175–193. 2005. View Article : Google Scholar : PubMed/NCBI
5	Campbell WB: New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol Sci. 21:125–127. 2000. View Article : Google Scholar : PubMed/NCBI
6	Chen JK, Capdevila J and Harris RC: Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol. 21:6322–6331. 2001. View Article : Google Scholar : PubMed/NCBI
7	Zhang Y, Oltman CL, Lu T, Lee HC, Dellsperger KC and VanRollins M: EET homologs potently dilate coronary microvessels and activate BK(Ca) channels. Am J Physiol Heart Circ Physiol. 280:H2430–H2440. 2001.PubMed/NCBI
8	Liu X, Wu J, Liu H, Lai G and Zhao Y: Disturbed ratio of renal 20-HETE/EETs is involved in androgen-induced hypertension in cytochrome P450 4F2 transgenic mice. Gene. 505:352–359. 2012. View Article : Google Scholar : PubMed/NCBI
9	Certíková Chábová V, Kramer HJ, Vanecková I, Thumová M, Skaroupková P, Tesar V, Falck JR, Imig JD and Cervenka L: The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. Kidney Blood Press Res. 30:335–346. 2007. View Article : Google Scholar : PubMed/NCBI
10	Eid S, Maalouf R, Jaffa AA, Nassif J, Hamdy A, Rashid A, Ziyadeh FN and Eid AA: 20-HETE and EETs in diabetic nephropathy: A novel mechanistic pathway. PLoS One. 8:e700292013. View Article : Google Scholar : PubMed/NCBI
11	Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, et al: Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 87:992–998. 2000. View Article : Google Scholar : PubMed/NCBI
12	Liu X, Zhao Y, Wang L, Yang X, Zheng Z, Zhang Y, Chen F and Liu H: Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure. Kidney Int. 75:1288–1296. 2009. View Article : Google Scholar : PubMed/NCBI
13	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, . Guide for the Care and Use of Laboratory Animals. 8th. National Academies Press; Washington (DC), USA: 2011, PubMed/NCBI
14	Liu Y, Dang H, Li D, Pang W, Hammock BD and Zhu Y: Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice. PLoS One. 7:e391652012. View Article : Google Scholar : PubMed/NCBI
15	Lai G, Wu J, Liu X and Zhao Y: 20-HETE induces hyperglycemia through the cAMP/PKA-PhK-GP pathway. Mol Endocrinol. 26:1907–1916. 2012. View Article : Google Scholar : PubMed/NCBI
16	Imig JD and Hammock BD: Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 8:794–805. 2009. View Article : Google Scholar : PubMed/NCBI
17	Singh H and Schwartzman ML: Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol Rep. 60:29–37. 2008.PubMed/NCBI
18	Imig JD, Zhao X, Capdevila JH, Morisseau C and Hammock BD: Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 39:690–694. 2002. View Article : Google Scholar : PubMed/NCBI
19	Kopkan L, Husková Z, Sporková A, Varcabová Š, Honetschlägerová Z, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Kramer HJ, et al: Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. Kidney Blood Press Res. 35:595–607. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM and Imig JD: Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 15:1244–1253. 2004.PubMed/NCBI
21	Ishizuka T, Cheng J, Singh H, Vitto MD, Manthati VL, Falck JR and Laniado-Schwartzman M: 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther. 324:103–110. 2008. View Article : Google Scholar : PubMed/NCBI
22	Luo P, Chang HH, Zhou Y, Zhang S, Hwang SH, Morisseau C, Wang CY, Inscho EW, Hammock BD and Wang MH: Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther. 334:430–438. 2010. View Article : Google Scholar : PubMed/NCBI
23	Fidelis P, Wilson L, Thomas K, Villalobos M and Oyekan AO: Renal function and vasomotor activity in mice lacking the Cyp4a14 gene. Exp Biol Med (Maywood). 235:1365–1374. 2010. View Article : Google Scholar : PubMed/NCBI
24	Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, Couse JF, Quigley R, Harder DR, Zhao X, et al: Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J. 22:4096–4108. 2008. View Article : Google Scholar : PubMed/NCBI
25	Luo G, Zeldin DC, Blaisdell JA, Hodgson E and Goldstein JA: Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. Arch Biochem Biophys. 357:45–57. 1998. View Article : Google Scholar : PubMed/NCBI
26	Pratt PF, Falck JR, Reddy KM, Kurian JB and Campbell WB: 20-HETE relaxes bovine coronary arteries through the release of prostacyclin. Hypertension. 31:237–241. 1998. View Article : Google Scholar : PubMed/NCBI
27	Oyekan AO: Differential effects of 20-hydroxyeicosatetraenoic acid on intrarenal blood flow in the rat. J Pharmacol Exp Ther. 313:1289–1295. 2005. View Article : Google Scholar : PubMed/NCBI